Warning letterFDA · Mar 30, 2021
Immune & Genetics Protocols, LLC MARCS-CMS 611042, March 30, 2021
Named company: Immune & Genetics Protocols, LLC
A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, the product fails to bear adequate…
Lot information: not specified in this record.